UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
October 2, 2007
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
Published: 08:32 02.10.2007 GMT+2 /HUGIN /Source:
Novo Nordisk A/S /CSE:NVOB /ISIN: DK0010280817
Transaction in Own Shares
Status re Novo Nordisk's holding of its own shares (30 September 2007)
In continuation of the company's announcement dated 31 January 2007 concerning a
planned share repurchase programme, and pursuant to Section 204.25 of the New
York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk
A/S (NYSE: NVO) and its wholly-owned affiliates on 30 September 2007 owned
9,925,484 of its own B shares of DKK 2, corresponding to a total nominal value
of DKK 19,850,968 or 3.07% of the total share capital. Hereof the wholly-owned
affiliates owned 99,000 B shares of DKK 2, corresponding to a total nominal
value of DKK 198,000 or 0.03% of the total share capital.
In the third quarter of 2007 4,518,750 B shares were repurchased by Novo Nordisk
A/S, and 107,880 B shares were disposed of to employees who exercised options
granted by Novo Nordisk.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 23,600 full-time
employees in 79 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For
more information, visit novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisik.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.co cqfr@novonordisk.com
Stock Exchange Announcement no 26 / 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: October 2, 2007 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer